Table 10Submission Quality

DescriptionYesNoComments
Population is relevant, with no critical intervention or relevant outcome missing.☐☒The modelled population did not reflect either the Health Canada indication nor the sponsor’s requested-reimbursement indication.
Model has been adequately programmed and has sufficient face validity.☒☐
Model structure is adequate for decision problem.☐☒See key limitation section.
Data incorporation into the model has been done adequately (e.g., parameters for probabilistic analysis).☐☒The model assumed treatment-specific utilities.
Parameter and structural uncertainty were adequately assessed; analyses were adequate to inform the decision problem.☐☒The number of treated bleeds that a patient experiences each year was included in the model as a fixed proportion.
The submission was well organized and complete; the information was easy to locate (clear and transparent reporting; technical documentation available in enough details).☒☐

From: Pharmacoeconomic Report: Emicizumab (Hemlibra)

Cover of Pharmacoeconomic Report: Emicizumab (Hemlibra)
Pharmacoeconomic Report: Emicizumab (Hemlibra): Hoffman-La Roche Ltd. Indication: Bleeding prevention, Hemophilia A [Internet]
Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.